DeCure for Isolated anhidrosis with normal sweat glands
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for isolated anhidrosis with normal sweat glands — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIsolated anhidrosis with normal sweat glands maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for isolated anhidrosis with normal sweat glands is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 58-year-old Caucasian man with heat intolerance, heat-induced cutaneous burning and no sweating for five years had a skin biopsy that disclosed no pathologies and no neurologic disorders. After diagnosis of acquired idiopathic generalized anhidrosis, treatment with methylprednisolone led to improvement of heat tolerance, remission of burning and partial remission of sweating. No other drug treatments are reported in these abstracts.
A 22-year-old male in Taiwan had generalized anhidrosis since infancy, except in axillae, forehead, palms and soles, with no other systemic abnormalities. Serial skin sections showed a lack of sweat glands, the first such case reported in Taiwan. This case differs from the others because the sweat glands are absent, not normal.
A case from Singapore of acquired idiopathic generalized anhidrosis responded well to conservative management with return of sweating activity. No drug was used. The abstracts note that approximately 100 cases have been reported worldwide, mostly in Japan, and that a 2014 case series from Singapore included 15 cases.
What is missing is any controlled trial of methylprednisolone or any other drug for this condition, any systematic comparison of steroid versus no treatment, and any understanding of why some patients have absent glands while others have normal glands. No patient stratification exists, and no funding for a trial is mentioned.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Dermatological Case Reports · 2014 · 7 citations · open access
Acquired idiopathic generalized anhidrosis
AbstractAnhidrosis is a failure in sweat production in response to physiological thermal or chemical stimuli. Acquired idiopathic generalized anhidrosis is a rare disorder without sweat gland pathology and without neurologic symptoms. Most cases have been reported from Far East. We report a case of a 58-year-old Caucasian male who suffered from heat intolerance, heat-induced cutaneous burning and failed to sweat even in sauna for five years. A skin biopsy disclosed no pathologies. He had no neurologic disorders. The diagnosis of acquired idiopathic generalized anhidrosis was confirmed and treatment with methylprednisolone initiated. This led to improvement of heat tolerance, remission of burning and partial remission of sweating.
Dermatologica Sinica · 2018 · 1 citations · open access
Idiopathic generalized anhidrosis with absence of sweat glands: A case report and literature review
AbstractIdiopathic generalized anhidrosis is a rare disease characterized by sweating impairment despite exposure to heat or exercise. It could be congenital or acquired. We reported a 22-year-old male with generalized anhidrosis, except axillae, forehead, palms and soles, since infancy. No other systemic abnormalities were found. Histopathology of serial sections revealed lack of sweat glands. It is the first case report of idiopathic generalized anhidrosis with absence of sweat glands in Taiwan.
Skin Health and Disease · 2023 · 1 citations · open access
Sudden Onset Anhidrosis in an Otherwise Healthy Male
AbstractAcquired idiopathic generalised anhidrosis (AIGA) is a rare disorder that is characterised by sudden onset generalised absence of sweating without any dermatological, neurological or sweat gland abnormalities. AIGA predominately affects young males, mostly involving patients of Asian descent. There have been approximately 100 reported cases worldwide, most of which were reported in Japan. In Singapore, it is rarely seen with one case series on 15 cases of AIGA reported in a 2014 study. Here, we present a case of AIGA who responded well to conservative management with sweating activity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
